Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.

Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

Instead of directly competing with dominant anti-CD20 therapies, Immunic strategically targets patients who need to switch due to side effects like infection risk. This go-to-market strategy carves out a valuable niche as a safer, long-term oral alternative without needing to prove superior efficacy upfront.

The drug's DHODH inhibition mechanism has antiviral properties. This is significant given recent findings that Epstein-Barr virus (EBV) is a prerequisite for developing MS. The therapy could potentially address a root cause by controlling EBV activity, a benefit beyond its primary anti-inflammatory and neuroprotective effects.

Although regulatory trials for relapsing MS focus on relapse rates as a primary endpoint, the CEO identifies "confirmed disability progression" as the most critical outcome for patients and physicians. This secondary endpoint is the true measure of a drug's ability to change the treatment landscape long-term.

Despite significant progress in managing symptoms for autoimmune conditions, very few treatments fundamentally alter the disease's course. The major unmet needs and investment opportunities lie in therapies that can induce remission or target common underlying pathologies like fibrosis, moving beyond mere symptom relief.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Diverging from typical approaches that focus on damaged neurons, Neuvivo's drug addresses ALS as an immune system disorder. By supplying a molecule the immune system is missing, it helps regulate the system, allowing the body to recover from the attacks that cause neurodegeneration.

While T-regs are most commonly associated with autoimmune conditions, Coya focuses on neurodegeneration. This strategy is based on their founder's research showing T-reg dysfunction is a major driver of diseases like ALS and FTD, applying a known biological mechanism to a novel, high-unmet-need therapeutic area.